OC and setipip news

[sdsurfin]

No news yet. Will keep you posted. Look to follicept for a possible near term option. Les keep our fingers crossed

[Popeyes]

How would we know what is an effective does orally?

[DrakeDuck]

Hey Hell,

I came across a thread on ************ about a setipiprant buy, and it looked like maybe you got it on it. Did you ever get any, and are you currently testing? Sorry if I missed any threads where you may have discussed this...I looked.

[Farkhairloss]

Any more news on whether Kane or anyone else is started manufacturing SM04554 or setipiprant?

[charlie76761]

Any more news on whether Kane or anyone else is started manufacturing SM04554 or setipiprant?

See earlier posts listed on my profile re SM: he needs more info on the compound - no one is 100% sure which molecule it is as there are a few wrt patencies by the development company

[lifelonglearning]

http://www.thestreet.com/video/13156...thera-ceo.html skip to 2 minutes confirms its oral drug

[lifelonglearning]

In February 2015, the Company entered into a licensing arrangement with Actelion and University of Pennsylvania pursuant to which it obtained exclusive worldwide rights to setipiprant, a clinical-stage selective and potent oral antagonist to the prostaglandin D 2 (PGD 2 ) receptor and exclusive worldwide rights to certain patent rights owned by the University of Pennsylvania covering the use of PGD 2 receptor antagonists for the treatment of hair loss. As part of the agreement, Actelion received an initial payment of $1,500,000 and will be eligible to receive up to an additional $25,500,000 in potential development and regulatory milestones, as well as royalties on sales if setipiprant is successfully commercialized. University of Pennsylvania will receive an initial payment of $100,000, certain annual license maintenance fees beginning in the third year of the agreement, as well as is eligible to receive up to $4,125,000 in milestone payments and royalties on sales of products commercialized under the patents provided for in the agreement.

[GSD]

http://www.thestreet.com/video/13156...thera-ceo.html skip to 2 minutes confirms its oral drug

"Only prevention"

[Swooping]

In February 2015, the Company entered into a licensing arrangement with Actelion and University of Pennsylvania pursuant to which it obtained exclusive worldwide rights to setipiprant, a clinical-stage selective and potent oral antagonist to the prostaglandin D 2 (PGD 2 ) receptor and exclusive worldwide rights to certain patent rights owned by the University of Pennsylvania covering the use of PGD 2 receptor antagonists for the treatment of hair loss. As part of the agreement, Actelion received an initial payment of $1,500,000 and will be eligible to receive up to an additional $25,500,000 in potential development and regulatory milestones, as well as royalties on sales if setipiprant is successfully commercialized. University of Pennsylvania will receive an initial payment of $100,000, certain annual license maintenance fees beginning in the third year of the agreement, as well as is eligible to receive up to $4,125,000 in milestone payments and royalties on sales of products commercialized under the patents provided for in the agreement.

As expected.. Pocket change. Actelion really wanted to get rid of that compound it seems. Going to be interesting to see what the trial will bring.

[mlamber5]

I think they have to say "only prevention." Cots himself has said he doesn't know if it will regrow hair in areas that already have hair loss or not. We already have a pretty damn good prevention drug on the market (finasteride). It very well may do more than just prevent hair loss/further hair loss.